$ONT

GRAHAM PETER purchased $432K of ONT

GRAHAM PETER purchased 25,140 shares of Onterris, Inc. (ONT) at $17.19 ($0.43M total) on 2026-06-05.

Original reporting
SEC EDGAR · GRAHAM PETER
Published Jun 8, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 8, 2026, 9:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ONT
Bullish
medium confidence
Mentioned
$ONT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ONTBullishLow
01

Why it matters

A director’s open-market purchase is incremental information about sentiment, but it does not change the company’s operating outlook based on the text provided.

02

Market read

Traders may treat the disclosure as a small sentiment input for ONT, but it is unlikely to drive a major repricing without accompanying fundamental news.

03

What to watch

The article provides no context on prior insider activity, total insider ownership changes, or whether the purchase was opportunistic versus planned.

Relevance 5/10Novelty 8/10Timing: filed 2026-06-08 (covers purchase dated 2026-06-05)

Background

The article summarizes an SEC Form 4 insider transaction for Onterris, Inc. (ONT).

Company-level read

Ticker impact

$ONTBullishMedium confidence
Context

Director Graham Peter bought 25,140 shares of Onterris (ONT) in an open-market transaction valued at $432,156.60, per Form 4.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless followed by additional disclosures.

Evidence & confidence

The filing is a primary-source insider transaction, but it does not include new company fundamentals (no guidance, trial, contract, or regulatory action).

Market effects

No sector-level read-across; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider buys under a non-10b5-1 plan can still be routine diversification/portfolio management and may not reflect near-term upside catalysts.

Key entities

  • Onterris, Inc.

    Company whose shares were purchased; insider transaction disclosed via SEC Form 4.

  • Graham Peter

    Director who purchased 25,140 shares of ONT for ~$432.2K.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ONTHigh

Onterris (ONT) Slashes Guidance, Launches Board Review

Onterris Inc. (NYSE:ONT) reported Q2 revenue of $186.7M, down from $234.5M YoY, and cut 2026 guidance. EBITDA margin improved to 17.1%. The company initiated a strategic review and adopted a poison pill. Net income fell to $1.4M, and operating cash flow turned negative. Hedge fund ownership declined, while short interest rose to 10.22%.

$ONTHighAI 8/10

Why is Oxford Nanopore Technologies stock sliding today?

Oxford Nanopore Technologies' shares fell 6.5% to 162.08p after Novo Holdings sold 49 million shares at a 12.3% discount. This follows mixed reactions to the company's H1 2026 results, showing revenue growth but geographic weaknesses. The UK's FTSE 100 also declined due to Middle East tensions and rising bond yields, impacting growth stocks like Oxford Nanopore.

$MRKHighAI 9/10

StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too

Merck (MRK) and Moderna (MRNA) announced positive Phase III results for their cancer vaccine, intismeran, showing improved outcomes when combined with Keytruda. Shares of both companies surged, with Moderna gaining 130.5% over three days. Sequencing companies like Illumina (ILMN) and PacBio (PACB) also saw gains due to the personalized nature of the therapy. Analysts upgraded Moderna's stock, citing broadened sales potential, while others remained cautious about long-term expectations.

$ONTHighAI 8/10

Why is Oxford Nanopore Technologies stock rallying today?

Oxford Nanopore Technologies' stock rose 6.6% after its interim results showed improved profitability, with gross margin expanding to 62.2% and adjusted EBITDA losses halving. The company also announced a new licensing deal expected to generate $20 million in fees. Berenberg maintained a Buy rating but lowered its price target to £2.00. The stock is still below its 52-week high of 215.6p.